Inclusion Criteria:

- Symptomatic multiple myeloma (MM) patient at the time of diagnosis (but not
necessarily at the time of relapse), according to International Myeloma Working Group
criteria.

- Patient having received conventional chemotherapy in 1st line treatment because of
age 65 years or over, or younger than 65 years and ineligible to high-dose therapy
plus stem cell transplantation.

- Measurable disease (≥10g/L monoclonal gammapathy and/or ≥ 200 mg/24h proteinuria or
involved serum free light chain ≥ 100mg/L with abnormal FLC ratio < 0.26 or > 1.65)

- Patient in 1st relapse or refractory to 1st line therapy. Relapse is defined by
M-component increase of ≥25% from baseline, in serum and/or urine (the absolute
increase in serum must be ≥ 5 g/l - the absolute increase of BJ proteins in urine
must be ≥200 mg/24 h). (It is recommended to treat only symptomatic or rapidly
evolutive relapses)

- Life expectancy of at least 3 months

- ECOG performance status <= 2 at study entry

- Laboratory test results within these ranges:

- Absolute neutrophil count >= 1.5 x 109/L

- Platelet count >= 100 x 109/L

- Serum creatinine <= 250 umol/l

- AST (SGOT) and ALT (SGPT) <= 3 x ULN

- Disease free of prior malignancies for >= 5 years, with exception of curatively
treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of
the cervix or breast

- Able to adhere to the study visit schedule and other protocol requirements

- Using effective contraceptive methods during and for 6 months after study treatment
(for fertile men, women of childbearing potential).

- Provision of informed consent.

- A period of at least 15 days must be respected between the last treatment of myeloma
and the beginning of the study.

Exclusion Criteria:

- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form.

- Any comorbidity which places the subject at unacceptable risk if he/she were to
participate in the study.

- Patients treated with high-dose therapy plus stem cell transplantation in 1st line
therapy

- Any prior use of bortezomib (Velcade) or bendamustine (Ribomustin)

- Concurrent use of other anti-cancer agents or treatments other than those stated in
this treatment plan

- Use of any other experimental drug or therapy within 28 days prior to the start of
study treatment.

- Known hypersensitivity to the study drugs

- Positive HIV serology, positive hepatitis C serology, active infection hepatitis A,
active infection hepatitis B.

- Severe cardiovascular disorders within 12 months prior to the start of study
treatment (e.g. myocardial infarct, ischemic episodes, arrhythmias)

- Previous major surgery less than 30 days before start of treatment

- Active infection,

- Pregnant or lactating women.